Research evidences that well-placed public-sector funding in life sciences drives considerable returns to the UK economy and society
Cambridge, 16th June 2020: Research led by an academic team from the University of Cambridge has demonstrated the benefits and outputs from the significant taxpayer investment into the Babraham Research Campus; evidencing the overall economic, social and scientific contribution the Campus makes to the UK economy. Commissioned by the Campus partners, Babraham Bioscience Technologies (BBT), the…
AT247 delivers significantly accelerated absorption of insulin compared to best in class treatments NovoRapid® and Fiasp®
Cambridge, UK., 15 June 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, presented positive results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247, at the American Diabetes Association 80th Scientific Sessions (ADA) virtual meeting. The abstract, #231-OR, is available on the ADA website.
Professor Thomas Pieber, Head of the Division of…
Pharmaceutical and biotech product development consultancy Boyds has hired regulatory professional Dr Lucie Hwang as associate in its award-winning regulatory affairs team that supports clients facilitating the fast and efficient development of medicinal products.
A specialist in the pharmaceutical development of biologics and ATMPs, clinical trial applications (CTAs), orphan drug designations (ODDs), gene therapies, and monoclonal Antibodies, Dr Hwang will focus on Boyds’ extensive strategic regulatory work and scientific advice requests for small molecules and advanced therapy medicinal…
AMSBIO reports on the pioneering work by researchers at the University of Sheffield, UK** to measure the interaction between the SARS-CoV-2 Spike S1 protein receptor binding domain (SARS-CoV-2 S1 RBD) and heparin. This has resulted in a new assay which could be a useful first screen for novel inhibitors of coronavirus infection.Evidence is mounting that SARS-CoV-2 uses heparan sulfates (HS) during the initial attachment to hosts cells, and this interaction appears to increase the affinity for the critical receptor, ACE2. The viral spike protein has a high affinity for heparin, particularly…
Cambridge, UK, 09 June 2020: CN Bio, a leading cell culture company that has developed single and multi-organ microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the publication of co-authored research led by researchers at the University of Cambridge in Nature Metabolism1, identifying a novel pathway that regulates the underlying mechanism of Non-Alcoholic Steatohepatitis (NASH), potentially a new therapeutic target. The collaborative work uses CN Bio’s NASH model to help elucidate the complex cellular mechanisms that cause liver…
Cambridge, UK., 10 June 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I Study Investigating the PD, PK and Safety of AT247 in comparison with NovoRapid® and Fiasp®’, has been selected for oral presentation at the upcoming American Diabetes Association 80th Scientific Sessions - Virtual (ADA) meeting which will be held from 12-16 June 2020. Abstract #231-OR will be available online from 14 June 2020.
The annual meeting of the ADA is the largest worldwide…
Onboarding is a crucial moment in the employee life cycle. However, the current circumstances mean traditional onboarding is not possible in most cases.
Onboarding is a critical step in the employee lifecycle and research shows that the quality of onboarding has a major impact on the overall job satisfaction and retention of employees. According to survey research, organisations considered in the top 20% in terms of onboarding had 91% first year retention and 62% of new hires reaching their first year goals compared with the bottom 30% of organisations which reported 30% and 17% goal…
Unlock structure-based drug design of challenging projects
For many biological targets of interest to pharma such as membrane proteins, structural information is difficult to obtain. The large size, complexity, and/or flexibility of these targets make them unsuitable for traditional structure determination techniques such as crystallography. Without structural insights to inform your drug design, you potentially miss out on discovering more effective drug candidates.
Solve your current structure-based drug design challenges with the first cryo-electron microscopy (cryo-EM) solution optimized…
Cambridge, United Kingdom – 4th June 2020 - Congenica, a digital health company enabling rapid analysis of complex genomic data, has launched Congenica Prenatal™, a new application on its platform that helps to facilitate faster, more accurate and comprehensive molecular research into fetal anomalies.
Prenatal research into genetic anomalies helps support the management of pregnancy, labor and appropriate pre- and post-natal treatment. It can also assist with identifying the recurrence risk in future pregnancies.
Routine ultrasound scanning detects anomalies in up to 5% of pregnancies, and…
Data will showcase capabilities of newly launched liquid biopsy assay for the detection of residual disease and recurrence
Research Triangle Park, NC, USA and Cambridge, UK, 04 June, 2020 -- Inivata, a leader in liquid biopsy, announces the presentation of new data supporting the Company’s newly launched RaDaR™ assay at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, taking place on 22-24 June 2020.
Posters will showcase RaDaR’s capabilities in the detection and monitoring of residual disease and recurrence in the plasma samples of patients previously…